MS: Busting the Myths
November 16, 2022 | Advocacy, Funding, Treatments
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]
June 8, 2022 | Covid-19, Treatments
If you have tested positive for COVID-19 and your symptoms started in the past 5 days and you are on Fingolimod or Ocrelizumab for your MS, you may be eligible for antiviral medication to treat COVID-19. Your GP can prescribe […]